BTCY - Biotricity, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5000
-0.0500 (-9.09%)
At close: 3:25PM EDT
Stock chart is not supported by your current browser
Previous Close0.5500
Open0.4500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4500 - 0.5500
52 Week Range0.4220 - 2.2500
Volume44,860
Avg. Volume25,306
Market Cap17.926M
Beta (3Y Monthly)4.14
PE Ratio (TTM)N/A
EPS (TTM)-0.2410
Earnings DateAug 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Biotricity CEO Waqaas Al-Siddiq in Live Interview on FOX Business Network

    Biotricity Inc. (OTCQB: BTCY), today announced that its CEO and Founder Waqaas Al-Siddiq will be on The Claman Countdown airing on Fox Business Network (FBN) on Wednesday, September 11th at 3:15 PM EDT. Mr. Al-Siddiq will discuss the current economic climate and how the Chinese tariff affects small and growing medical device companies, and ultimately, US patients.

  • GlobeNewswire

    BiotricityReports Fiscal Q1 ResultsShowingA Strong Growth Trajectory

    After achieving FDA clearance, the Company’s first remote patient monitoring (RPM) solution, Bioflux, experienced a high adoption rate during its fiscal 2018 limited market release to anchor clinics. In the first three months of fiscal year 2019, the Company has transitioned to full US release, ramping up its small sales force and expanding its sales footprint to 11 key states, with plans to expand further. This shift has the potential to improve patient care and save additional lives while also saving significant healthcare costs.

  • Why single payer can help address health care's grey areas: Digital health execs
    Yahoo Finance

    Why single payer can help address health care's grey areas: Digital health execs

    Two digital health officials told Yahoo Finance recently that Medicare for All could help address some of the industry’s toughest challenges.

  • GlobeNewswire

    Biotricity CEO Waqaas Al-Siddiq in Live Interview on Yahoo Finance

    Biotricity Inc. (OTCQB: BTCY), today announced that its CEO and Founder Waqaas Al-Siddiq will be on Yahoo Finance’s On the Move show on Tuesday, August 20th, airing at 11:45 AM EDT. Mr. Al-Siddiq will discuss American healthcare coverage and how insurance plans, whether public or private, impact growing, start-up medical device companies. Currently, more than seven million patients benefit from remote monitoring and the use of connected medical devices, and nearly 1,800 hospitals in the US are using mobile applications to improve risk management and care quality.

  • GlobeNewswire

    Biotricity Audited Year-End Results Demonstrate Execution of Commercial Growth Plans

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has completed its 10-K filing for the fiscal year, which ended March 31, 2019. The increase in revenues reaffirms the Company’s positive commercialization progress. Increased Market Penetration: Without including future new device placements, revenue run rates for Biotricity’s current installed customer base are projected to deliver over $2 million in recurring technology fees over the next 12 months.

  • GlobeNewswire

    Biotricity Doubles Sales Force – Expands Device Fleet by 59%

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has  expanded its fleet of Bioflux devices to meet customer demand. “Our sales expansion is yielding results and we see a consistent increase in sales as a result of our anchor clients recommending us to other medical professionals,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. Long-term, we are a technology company with a pipeline of complimentary remote patient monitoring and pre-emptive diagnostic technologies that will allow us to leapfrog and build on our existing platform.

  • GlobeNewswire

    Biotricity Provides Fiscal Fourth Quarter Update: Sales Force Expansion to Fuel Growth

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today provided a progress report for its fiscal 2018 fourth quarter, which ended March 31, 2019. The company continues to execute its plans to grow its sales force, expand its geographic footprint, and reach more Americans with its life-saving technology. The company’s flagship product, Bioflux, was met with a high adoption rate in the clinical community throughout the soft launch of the past year, leading to positive customer feedback and steady re-order rates.

  • GlobeNewswire

    Biotricity Achieves Market Expansion in Two New States

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, has expanded its sales team to cover two additional states in the US that are key to driving faster adoption of its flagship product, Bioflux. The Company has been experiencing great traction with its technology in the marketplace and is taking the opportunity to capitalize on its momentum and increase its regional footprint. The Company’s remote patient monitoring device Bioflux monitors a patient’s ECG in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology.

  • GlobeNewswire

    Biotricity Announces Expanded R&D Team for the Development of its Fetal/Maternal and Ambulatory Wellness Monitoring Systems

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to announce further buildout of its R&D team, with the engagement of the Biomedical Engineering Department at the University of Calgary. The expanded team will include a Biomedical Engineering (BME) fellow under Dr. Ferber, Director of Biomedical Engineering’s Human Performance Laboratory, who will explore and develop effective representations of both fetal/maternal heart rate variability (HRV) and electro-hysterography (labor contraction monitoring) in pregnancy.

  • GlobeNewswire

    Biotricity Achieves Significant Milestones for Both Fetal/Maternal and Ambulatory Wellness Monitoring Systems

    Biotricity, Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that it has achieved significant progress in their University of Calgary-based R & D program for their latest wellness monitoring systems. Clinical data collection has commenced for both its fetal/maternal and ambulatory adult heart rate variability (HRV) monitoring systems. Dr. David Liepert, QA/QI and Safety Lead and Director for the University of Calgary Cumming School of Medicine Department of Anesthesia commented, “We could not be more excited to participate in developing both these non-invasive medical-grade ambulatory monitors, utilizing the amazing fidelity and mobility of the Bioflux system.

  • GlobeNewswire

    Biotricity Provides End of Year Shareholder Update

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, is providing an end of year update to its shareholders. “2018 was an exciting year for Biotricity as we launched our first medical-grade device into the growing cardiac market and received great reception from our initial sales forays,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. The Company experienced a 211% growth in sales from Q2 2018 to Q3 2018.

  • GlobeNewswire

    Biotricity Actively Pursues Holter Market with Bioflux Product Offering

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will be actively pursuing the Holter market in addition to the MCT market with its Bioflux product offering, expanding its revenue growth opportunities. Bioflux is a 3 in 1 monitoring solution, offering mobile cardiac telemetry (MCT), event, and Holter monitoring.

  • GlobeNewswire

    Biotricity Builds Capacity with University of Calgary and Receives Ethics Approvals for Research

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced the launch of its 2019 R&D program at the University of Calgary. The Company is initiating a series of investigations using the 1000 Hz fidelity of Bioflux to facilitate ambulatory Heart Rate Variability (HRV) monitoring for maternity and in both major and emergency surgery patients at Rockyview General Hospital in Calgary. Successful results will open up two growing remote monitoring (RPM) markets for Biotricity’s technology: maternal and post-operative remote monitoring.

  • ACCESSWIRE

    An Unknown Stock and a $50B Regulatory Trend Could Result in a Cannabis Like Breakout

    A major shift in healthcare could rival this new industry as the biggest health insurer in the U.S., Medicare & Medicaid, tries to save money by moving more procedures (and patients) out of hospitals into smaller surgical centers and get them out of the surgical setting rapidly. Medicare is already saving billions each year according to a recent study and is hoping to save almost $60 billion in the coming years through this huge cost cutting measure. Remote patient monitoring, already a big and lucrative business, is likely to become a whole lot larger.

  • GlobeNewswire

    Distinguished Physicians Join Biotricity’s Newly Formed Scientific and Medical Alliance Board

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that Drs. Donald S. (Buck) Cross, Edward Lazaga, Imran Mohiuddin, Radoslaw (Stefan) Kiesz, and Tea Acuff will be joining the Company’s Scientific and Medical Alliance Board. “We are fortunate to add such high caliber physicians to our Scientific and Medical Alliance Board,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. The Company is leveraging the success of its RPM platform within Bioflux and applying it in remote patient monitoring solutions for a wide array of chronic conditions that will help aid disease management and improve patient engagement.